Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43146 (
tumour suppressor
)
5,935
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
AT-rich interactive domain-containing protein 1A
(
ARID1A
) has been shown to function as a
tumour suppressor
in various malignancies. However, the biological role of
ARID1A
in osteosarcoma is not clear. The present study aimed to investigate the expression pattern, prognostic value and the biological role of
ARID1A
in human osteosarcoma.
ARID1A
expression in 53 osteosarcoma surgical specimens was examined by quantitative real-time polymerase chain reaction, and its clinical significance was analysed. The role of
ARID1A
in cell proliferation, apoptosis, and metastasis were examined.
ARID1A
mRNA expression were significantly down-regulated in osteosarcoma tumours from that in matched adjacent non-tumour tissues.
ARID1A
expression was significantly inversely correlated with tumour stage and distant metastasis, as well as poor overall survival in patients with osteosarcoma. Furthermore,
ARID1A
mRNA was down-regulated in four human osteosarcoma cell lines MG-63, U2OS, HOS and Saos-2. Restoring of
ARID1A
expression in MG-63 and U2OS cells significantly inhibited cell proliferation and metastasis in vitro. Collectively, our data demonstrate that
ARID1A
may serve as a
tumour suppressor
in osteosarcoma progression, and represent a valuable prognostic marker and potential therapeutic target for osteosarcoma.
...
PMID:Low Arid1a Expression Correlates with Poor Prognosis and Promotes Cell Proliferation and Metastasis in Osteosarcoma. 2917 69
AT-rich interactive domain 1A (ARID1A, as known as
BAF250a
) is a subunit of human switch/sucrose nonfermentable chromatin remodeling complex with
tumour suppressor
function. Mutations of Arid1a have been reported in many human cancers and low expression of this protein has been correlated to a poor prognosis outcome in patients affected by some types of cancer. Although there are many studies regarding ARID1A functions in cancer, little is known about its role in regulating cell differentiation and normal tissues homeostasis. Here, we investigate ARID1A expression in normal placental tissues of first and third trimester of gestation and in pathological placental tissues of pregnancy complicated by preeclampsia (PE) and intrauterine growth restriction (IUGR) to evaluate a possible role of this protein in trophoblast differentiation. We found that ARID1A was specifically expressed in villous and extravillous cytotrophoblastic cells in normal placentas whereas syncytiotrophoblast was negative. Interestingly, ARID1A was expressed in both cytotrophoblastic cells and syncytiotrophoblast in placentas affected by PE and PE-IUGR. Moreover, ARID1A was also present in syncitial knots of pathological placentas. The present results indicate that ARID1A is a good marker of poor trophoblast differentiation in these pathologies, because the significant high positive staining in syncytiotrophoblast nuclei may suggest a poor differentiation of this trophoblast layer due to the cytotrophoblast cells fusion with the syncytiotrophoblast overlaying before arresting their cell cycle.
...
PMID:AT-rich interactive domain 1A protein expression in normal and pathological pregnancies complicated by preeclampsia. 3252 96